Posted by Michael Wonder on 05 Jan 2023
FoundationOne Liquid CDx receives FDA approval as a companion diagnostic for Rozlytrek (entrectinib)
4 January 2023 - Foundation Medicine’s liquid biopsy test can now be used by oncologists to identify more patients with rare mutations within their cancer for whom treatment with Rozlytrek may be appropriate.
Foundation Medicine today announced that the US FDA has approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify patients with ROS1 positive non-small-cell lung cancer, or patients with NTRK fusion positive solid tumours, who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib).
